종양학 영양 시장 : 암 유형별, 제품 유형별, 제형별, 투여 경로별, 투여 유형별, 최종 용도별 - 세계 예측(2024-2032년)

Oncology Nutrition Market size will reach an 8.1% CAGR from 2024 to 2032, fueled by the increasing awareness of nutrition's crucial role in cancer treatment, coupled with advancements in medical research. As healthcare providers and patients recognize the benefits of tailored nutritional support in managing treatment side effects and improving outcomes, demand for specialized oncology nutrition products is rising. Ongoing research continues to refine nutritional strategies, highlighting their impact on patient recovery and quality of life. These factors collectively drive innovation and investment in the field, fostering market growth and improving patient care standards.

For instance, in June 2024, DAE, in partnership with IDRS Labs, introduced 'AKTOCYTE,' a nutraceutical for cancer patients undergoing radiotherapy aimed at improving their quality of life during treatment. It indicates a trend towards innovation in supportive care strategies aimed at enhancing patients' quality of life and managing treatment-related challenges more effectively. Moreover, such initiatives underscore increasing collaboration between scientific institutions and industry to address specific nutritional needs in oncology, potentially driving further growth and development in this market.

The oncology nutrition industry is divided based on cancer type, product type, formulation, route of administration, dosage type, end-use, and region.

The esophageal segment will garner noteworthy gains through 2032, owing to the high incidence of esophageal cancer worldwide. Patients with esophageal cancer often experience difficulties in swallowing, leading to challenges in nutrient intake and digestion. This necessitates specialized nutritional support tailored to their needs, driving the demand for oncology nutrition products. Additionally, advancements in medical treatments and increasing awareness about the importance of nutritional support in cancer care are further propelling the growth of the esophageal segment in the oncology nutrition market.

The vitamins and minerals segment will experience a significant upturn by 2032, driven by the critical role these nutrients play in supporting immune function and overall health during cancer treatment. Patients often require supplementation to counteract treatment-related side effects and support recovery. Increasing awareness among healthcare providers about personalized nutrition and the efficacy of vitamins and minerals in enhancing treatment outcomes further propels market growth. Continuous innovation in nutritional formulations tailored to oncology patients underscores the segment's pivotal role in the evolving landscape of cancer care.

Asia Pacific oncology nutrition industry share will record a notable CAGR during 2024 and 2032 due to its rapidly growing population, increasing prevalence of cancer, and rising healthcare expenditure. Additionally, the region's expanding middle class and improving healthcare infrastructure are driving demand for specialized nutritional products for cancer patients. Significant investments in research and development by local and international players are also bolstering market growth. The region's robust economic growth and urbanization further make the Asia Pacific a key contributor to the oncology nutrition market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of cancer
    • 3.2.1.2 Growing awareness of nutrition's role in cancer care
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of specialized oncology nutrition products
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Porter's analysis
• 3.5 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company positioning matrix
• 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Head and neck cancer
• 5.3 Stomach and gastrointestinal cancer
• 5.4 Esophageal cancer
• 5.5 Liver cancer
• 5.6 Breast cancer
• 5.7 Pancreatic cancer
• 5.8 Lung cancer
• 5.9 Other cancer types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Vitamins and minerals
• 6.3 Proteins
• 6.4 Antioxidants
• 6.5 Other product types

Chapter 7 Market Estimates and Forecast, By Formulation, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Standard
• 7.3 Elemental

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By Dosage Type, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Liquid
• 9.3 Powder
• 9.4 Other dosage types

Chapter 10 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Hospitals
• 10.3 Clinics
• 10.4 Homecare
• 10.5 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Abbott Laboratories
• 12.2 Baxter International Inc.
• 12.3 B. Braun Melsungen AG
• 12.4 Danone (Nutricia)
• 12.5 Fresenius SE & Co. KGaA
• 12.6 Grifol S.A.
• 12.7 Hormel Foods Corporation
• 12.8 Meiji Holdings Co., Ltd.
• 12.9 Medtrition Inc.
• 12.10 Nestle S.A.
• 12.11 Victus, Inc.